Trust Co. of Toledo NA OH raised its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,431 shares of the company’s stock after buying an additional 70 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Zoetis were worth $233,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of ZTS. Darwin Wealth Management LLC bought a new position in Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services bought a new position in Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new position in Zoetis in the third quarter valued at approximately $33,000. Dunhill Financial LLC lifted its stake in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Quarry LP lifted its stake in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the stock. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $211.89.
Zoetis Stock Performance
NYSE ZTS opened at $166.31 on Tuesday. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The firm’s fifty day moving average price is $171.53 and its two-hundred day moving average price is $180.22. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The firm has a market capitalization of $75.03 billion, a P/E ratio of 31.26, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the company earned $1.36 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current year.
Zoetis Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a $0.50 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s payout ratio is currently 37.59%.
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- What Are Growth Stocks and Investing in Them
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- About the Markup Calculator
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Upcoming IPO Stock Lockup Period, Explained
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.